Study funded by Sobi and Sanofi.

Publication

EAHAD •
7 February, 2025 •
•

Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program

Anthony K. C. Chan, Flora Peyvandi, Annette von Drygalski, Sandrine Meunier, Elena Santagostino, Linda Bystrická, Jennifer Dumont , Lara Mamikonian, Umer Khan, Liane Khoo, Robert Klamroth

Available materials

Oral Presentation

Publication

EAHAD •
7 February, 2025 •
•

Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Hemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study

Lynn Malec, Beatrice Nolan, Anthony K. C. Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Oral Presentation

Publication

EAHAD •
5 February, 2025 •
•

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study

Olga Benitez Hidalgo, Anna Olsson, Karina Meijer, Carmen Escuriola-Ettingshausen, Flora Peyvandi, Andreu Schoenenberger López, Markus Fusser, Stefan Lethagen

Available materials

Poster

Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed

Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program

Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Hemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study

Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Long-term observational joint health study in patients initiating efanesoctocog alfa: baseline data

Observational Study of Prophylactic Efanesoctocog Alfa for Joint Health in Hemophilia A: PROTECT-ALT

Joint health outcomes with efanesoctocog alfa in adults/adolescents from XTEND-1 continuing XTEND-ed